Wealthfront Advisers LLC Lowers Stock Holdings in Boston Scientific Corporation $BSX

Wealthfront Advisers LLC trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 21.5% during the 1st quarter, HoldingsChannel reports. The fund owned 99,104 shares of the medical equipment provider’s stock after selling 27,180 shares during the quarter. Wealthfront Advisers LLC’s holdings in Boston Scientific were worth $6,219,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BSX. FWL Investment Management LLC bought a new position in Boston Scientific in the 2nd quarter valued at approximately $26,000. Swiss RE Ltd. purchased a new position in Boston Scientific in the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific in the fourth quarter worth approximately $26,000. Bangor Savings Bank boosted its stake in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund purchased a new position in Boston Scientific during the fourth quarter valued at $29,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $43.95 on Friday. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The firm has a market cap of $65.33 billion, a P/E ratio of 18.39, a P/E/G ratio of 0.84 and a beta of 0.58. The stock’s fifty day moving average price is $48.18 and its 200-day moving average price is $65.87.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 3.35 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a share buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BSX. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Evercore set a $65.00 price target on Boston Scientific in a report on Monday, July 6th. Citigroup reduced their target price on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, May 28th. Truist Financial cut their target price on Boston Scientific from $64.00 to $62.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Oppenheimer set a $90.00 price target on shares of Boston Scientific in a report on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $79.84.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $56.68 per share, with a total value of $202,914.40. Following the transaction, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director David C. Habiger purchased 2,250 shares of the stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.